©2022 Stanford Medicine
Allogeneic HCT Using Nonmyeloablative Host Conditioning With TLI & ATG vs SOC in AML
Not Recruiting
Trial ID: NCT00568633
Purpose
Acute myeloid leukemia (AML) is a cancer of the bone marrow that mostly affects older adults.
Even with the best chemotherapy, two-year disease-free survival is achieved in a minority of
patients. Bone marrow transplantation from a sibling donor may improve cure rates; however,
patients over 50 years of age have a high risk of complications and therefore generally are
excluded from this treatment option. Recently our group developed a transplantation strategy
for older cancer patients that protects against transplant-associated complications, yet does
not interfere with the ability of the transplanted donor cells to destroy cancer cells. With
this new method, we can now safely evaluate transplantation as a curative therapy for AML
patients over the age of 50. We have assembled clinical and scientific researchers throughout
the state of California to study and compare bone marrow transplantation using our new
approach with the best standard of care chemotherapy in AML patients over the age of 50. The
results of this study have the potential to establish a new treatment standard that will
improve survival of older AML patients.
Official Title
A California Cooperative Clinical Study Comparing Allogeneic Hematopoietic Cell Transplantation Using Nonmyeloablative Host Conditioning With Total Lymphoid Irradiation and Anti-thymocyte Globulin Versus Best Standard of Care in Acute Myeloid Leukemia (AML) in First Complete Remission
Stanford Investigator(s)
Robert Lowsky
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Jason Gotlib
Professor of Medicine (Hematology)
Sally Arai
Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Richard Hoppe
Henry S. Kaplan-Harry Lebeson Professor of Cancer Biology
Judith Shizuru
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy) and of Pediatrics (Stem Cell Transplantation)
Laura Johnston
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Robert Negrin
Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy)
Wen-Kai Weng, MD, PhD
Associate Professor of Medicine (Blood and Marrow Transplantation and Cellular Therapy) and, by courtesy, of Dermatology
Eligibility
INCLUSION CRITERIA
- ≥ 50 years of age and ≤ 75 years of age.
- De novo acute myelogenous leukemia (AML), based on FAB and WHO criteria.
- Intermediate or unfavorable cytogenetic abnormalities based on Southwest Oncology
Group (SWOG) Cytogenetic Criteria.
- First morphologic complete remission (CR), or CRp (a complete remission but with low
platelets) following 1 or 2 courses of induction therapy, documented no more than 8
weeks prior to the date of enrollment and confirmed at time of enrollment.
- Karnofsky Performance Score ≥ 60.
- Suitable for non-myeloablative transplantation or best treatment.
- Able to understand and willing to sign a written informed consent document.
EXCLUSION CRITERIA
- AML with favorable cytogenetic features based on SWOG Cytogenetic Criteria
- AML, either treatment-related or MDS-related
- Active CNS disease as identified by positive CSF cytospin at time of enrollment.
- Prior or concurrent malignancies except localized non-melanoma skin malignancies or
treated cervical carcinoma in situ. (EXCEPTION: Cancer treated with curative intent >
5 years previously is allowed. EXCEPTION: Low grade lymphoma is allowed as long as
active treatment is not required for control of disease)
- Planned for allogeneic transplant using a full-dose conditioning
- Life expectancy < 1 year due to diseases other than malignancy
- Pregnant or breastfeeding.
- HIV-seropositive.
- Uncontrolled infection (presumed or documented) with progression after appropriate
therapy for greater than one month.
- Symptomatic coronary artery disease or uncontrolled congestive heart failure. Left
ventricular ejection fraction (LVEF) is not required to be measured, however if
measured, exclusion if ejection fraction is < 30%.
- Requiring supplementary continuous oxygen. Diffusing capacity of the lungs for carbon
monoxide (DLCO) is not required to be measured, however if it is measured, exclusion
if DLCO < 35%.
- Fulminant liver failure
- Cirrhosis with evidence of portal hypertension or bridging fibrosis
- Alcoholic hepatitis
- Esophageal varices
- A history of bleeding esophageal varices
- Hepatic encephalopathy
- Uncorrectable hepatic synthetic dysfunction evidenced by prolongation of the
prothrombin time
- Ascites related to portal hypertension
- Chronic viral hepatitis with total serum bilirubin > 3 mg/dL
- Symptomatic biliary disease
Intervention(s):
procedure: Allogeneic HSCT
drug: Anti-thymocyte globulin (ATG)
drug: Cyclosporine (CSP)
drug: Mycophenolate mofetil (MMF)
radiation: Total lymphoid irradiation (TLI)
drug: Methylprednisolone sodium succinate
drug: Best standard care
Not Recruiting
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
BMT Referrals
650-725-1647